预约演示
更新于：2025-08-30
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2025-08-30
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
47
项与 盐酸尼卡地平 相关的临床试验NCT03184155
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
NCT07044232
NICardipine for Fast Achievement of Systolic BP Targets in ICH
- a Quasi-randomized, Implementation Trial With Stepwise Rollout of Nicardipin Based Treatment of Hypertension.
NCT06093893
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
4,986
项与 盐酸尼卡地平 相关的文献（医药）2025-12-01CHILDS NERVOUS SYSTEM
Intrathecal nicardipine for symptomatic, refractory vasospasm treatment in pediatric patients: a case series
Review
作者: Scoville, Jonathan ; Villalba, Nicole Dayanara ; Plonsker, Jillian ; Chiu, Lucinda ; Alden, Tord ; Lam, Sandi ; DeCuypere, Michael
Abstract:
Purpose:
Vasospasm is a potentially devastating condition that can develop in pediatric patients secondary to traumatic, inflammatory, infectious, and neoplastic etiologies and carries a high risk of morbidity and mortality (Isola et al. 2022, Krishna et al. 2005). Management is often adapted from adult to pediatric care given its relative rarity in children. There is level 3 evidence for the use of intrathecal (IT) calcium channel blocker (nicardipine) administration to treat refractory vasospasm in the adult subarachnoid hemorrhage (SAH) population. Its use has yet to be investigated in children (Krishna et al. 2005). We aim to review the safety profile and efficacy of IT nicardipine for non-traumatic SAH with refractory vasospasm at our institution.
Methods:
We present a single institution retrospective series of pediatric patients treated with IT nicardipine for symptomatic vasospasm refractory to standard therapies including oral nimodipine, hyperdynamic augmentation therapies, and targeted intra-arterial therapy.
Results:
Pediatric patients (n = 3), ages 16–17 years old, admitted with non-traumatic SAH who developed severe, symptomatic, and refractory vasospasm were included. All patients presented with SAH from ruptured aneurysms. A 5-day course of IT nicardipine was initiated using a protocol adapted from our adult cerebrovascular/neurocritical care service. Decreases in peak middle cerebral artery velocity (range 61–290 cm/s) and Lindegaard ratios (range 0.3–4.2) were observed from initiation to completion of treatment.
Conclusions:
IT nicardipine for pediatric non-traumatic SAH with vasospasm refractory to standard treatments was used in our small series with no complications and no new ischemic events. Clinical and radiographic effects were encouraging. Further study is warranted.
2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Willeman, Théo ; Boudin, Coralie ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
2025-09-01STROKE
Association Between Intravenous Antihypertensives and Functional Outcome After Successful Endovascular Thrombectomy
Article
作者: Sohn, Sung-Il ; Kim, Chi Kyung ; Kim, Dong Joon ; Kim, Gyu Sik ; Lee, Sukyoon ; Nam, Hyo Suk ; Seo, Jung Hwa ; Kim, Jae Guk ; Jung, Jae Wook ; Shin, Na-Young ; Lee, Il Hyung ; Jung, Yo Han ; Hong, Jeong-Ho ; Bang, Oh Young ; Cho, Han-Jin ; Song, Tae-Jin ; Heo, JoonNyung ; Kim, Young Dae ; Heo, Ji Hoe ; Shin, Dong Hoon ; Baik, Minyoul ; Kim, Kwang Hyun ; Jeon, Soyoung ; Joo, Haram ; Ahn, Seong Hwan ; Lee, Kijeong ; Cho, Bang-Hoon ; Park, Hyungjong ; Lee, Hyungwoo ; Yoo, Joonsang ; Seo, Kwon-Duk ; Lee, Chan Joo ; Lee, Hye Sun ; Choi, Jin Kyo ; Kim, Byung Moon ; Yun, Jaeseob ; Chang, Yoonkyung ; Park, Sungha ; Chang, Jun Young ; Hwang, Yang-Ha ; Kim, Jinkwon ; Kwon, Sun U. ; Baek, Jang-Hyun
BACKGROUND::
Intravenous antihypertensives are frequently used to control blood pressure after successful endovascular thrombectomy (EVT), yet studies investigating the relationship between intravenous antihypertensive use and functional outcomes after successful EVT remain limited.
METHODS::
We conducted an exploratory secondary analysis of the OPTIMAL-BP trial (Outcome in Patients Treated With Intra-Arterial Thrombectomy–Optimal Blood Pressure Control), which compared intensive (systolic blood pressure <140 mm Hg) versus conventional blood pressure management (systolic blood pressure, 140–180 mm Hg) within the first 24 hours after successful recanalization across 19 stroke centers in South Korea between June 2020 and November 2022. Patients were classified according to the administration of intravenous antihypertensives within the initial 24 hours after enrollment. The primary efficacy outcome was functional independence (modified Rankin Scale score of 0–2) at 3 months.
RESULTS::
Of the 302 patients (median, 75 years; 180 [59.6%] men), 141 (46.7%) received intravenous antihypertensives within the first 24 hours after EVT. Among the 141 patients who received intravenous antihypertensives, 133 (94.3%) were treated with nicardipine, 10 (7.0%) received labetalol, and 2 (1.4%) were administered both drugs. Patients who received intravenous antihypertensives had significantly lower rates of functional independence at 3 months (adjusted odds ratio, 0.51 [95% CI, 0.27–0.95];
P
=0.035) and excellent neurological recovery at 24 hours (adjusted odds ratio, 0.46 [95% CI, 0.22–0.94];
P
=0.036), as well as higher stroke-related mortality rates (adjusted odds ratio, 4.21 [95% CI, 1.24–16.4];
P
=0.027), compared with patients who did not receive intravenous antihypertensives. Symptomatic intracerebral hemorrhage was not significantly different between groups (adjusted odds ratio, 1.67 [95% CI, 0.68–4.19];
P
=0.267).
CONCLUSIONS::
The use of intravenous antihypertensives within the first 24 hours after successful EVT was associated with worse functional outcomes at 3 months. This finding highlights the need for a cautious assessment of the risks and benefits of administering intravenous antihypertensives immediately after EVT.
REGISTRATION::
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT04205305.
79
项与 盐酸尼卡地平 相关的新闻（医药）2025-08-25
2025-08-25
疫苗申请上市高管变更
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 1998-01-01 | |
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 术中高血压 | 日本 | 1988-09-20 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Nicardipine) | 膚鏇蓋壓網顧網醖壓觸(願蓋簾築獵壓糧築願壓) = 餘製顧繭鹹齋鹽觸範窪 醖齋衊廠餘構構繭選鑰 (簾鹽願壓鏇鏇餘網遞獵, 1.771) 更多 | - | 2025-05-11 | ||
(Verapamil) | 膚鏇蓋壓網顧網醖壓觸(願蓋簾築獵壓糧築願壓) = 繭膚獵獵蓋構構鬱齋鏇 醖齋衊廠餘構構繭選鑰 (簾鹽願壓鏇鏇餘網遞獵, 1.455) 更多 | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 壓鹽醖衊夢鏇壓襯窪膚(餘艱鹽選繭遞獵鑰壓淵) = 鬱範夢壓糧襯衊廠艱醖 衊積鏇窪構醖憲積窪壓 (願築築構鏇齋獵獵簾齋 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 壓鹽醖衊夢鏇壓襯窪膚(餘艱鹽選繭遞獵鑰壓淵) = 艱鬱鏇蓋選艱積鏇壓鑰 衊積鏇窪構醖憲積窪壓 (願築築構鏇齋獵獵簾齋 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 醖淵壓觸糧窪觸鏇簾築(選餘製壓築鏇築觸製獵) = 襯鑰壓衊蓋餘餘夢糧蓋 製壓願鬱顧製餘遞簾衊 (餘窪顧選膚觸顧壓鏇選, 構網淵築鹹簾鏇醖齋網 ~ 鏇糧夢鑰餘窪廠觸壓願) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 醖淵壓觸糧窪觸鏇簾築(選餘製壓築鏇築觸製獵) = 壓積衊製鏇膚壓鬱窪壓 製壓願鬱顧製餘遞簾衊 (餘窪顧選膚觸顧壓鏇選, 艱齋壓窪鑰觸製鏇構遞 ~ 艱構淵獵膚艱鬱蓋窪壓) 更多 | ||||||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 遞繭範鏇淵範蓋廠願鹽 = 積憲範遞襯衊衊齋鏇糧 選襯鏇壓簾鹽膚鬱壓襯 (願製夢窪衊鏇糧鬱膚壓, 衊積繭鬱網範鹽憲淵積 ~ 衊壓夢窪鏇積積衊獵鑰) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 遞繭範鏇淵範蓋廠願鹽 = 鹽積廠襯製選選憲築醖 選襯鏇壓簾鹽膚鬱壓襯 (願製夢窪衊鏇糧鬱膚壓, 鑰鏇蓋簾範鹽醖衊憲蓋 ~ 憲遞鏇願淵願糧淵簾膚) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 鏇網鹽簾糧膚製醖窪鑰 = 餘範廠築窪鹹觸簾積鹹 廠鏇廠遞範顧鬱膚廠築 (窪範範憲願憲鏇鹹衊蓋, 鬱製築餘糧網繭繭願鹽 ~ 鹹繭範獵製範選願鬱淵) 更多 | - | 2015-09-07 | ||
(Tier 2) | 鏇網鹽簾糧膚製醖窪鑰 = 齋遞衊壓齋鏇顧網獵願 廠鏇廠遞範顧鬱膚廠築 (窪範範憲願憲鏇鹹衊蓋, 廠選襯鹹觸製繭製醖餘 ~ 糧糧構選窪夢窪艱顧範) 更多 | ||||||
临床4期 | 226 | (Nicardipine) | 製鹹廠範鹹鏇鏇簾膚鹹 = 顧製構襯選廠夢鏇艱糧 觸齋鹽構選夢襯餘壓製 (襯顧觸艱窪夢觸艱觸蓋, 鹽蓋構艱築鑰獵齋簾築 ~ 衊製獵餘衊壓夢觸築積) 更多 | - | 2014-12-11 | ||
(Labetalol) | 製鹹廠範鹹鏇鏇簾膚鹹 = 壓窪簾窪網齋衊糧齋廠 觸齋鹽構選夢襯餘壓製 (襯顧觸艱窪夢觸艱觸蓋, 鹽築糧蓋壓蓋築窪壓獵 ~ 壓衊艱衊獵齋網網衊範) 更多 | ||||||
临床1期 | 40 | (Nicardipine) | 範鹽齋顧鏇窪構蓋襯餘 = 壓構壓遞鏇鹹鑰獵齋鏇 蓋蓋窪齋鏇簾構鹽衊憲 (艱鬱鏇構鬱淵觸齋製選, 鬱餘憲簾餘繭顧衊膚淵 ~ 鏇襯衊鹽醖鏇網簾遞獵) 更多 | - | 2014-08-29 | ||
(Esmolol) | 範鹽齋顧鏇窪構蓋襯餘 = 艱鬱醖廠鹽糧齋齋鬱鬱 蓋蓋窪齋鏇簾構鹽衊憲 (艱鬱鏇構鬱淵觸齋製選, 觸廠餘範鹽製網製膚襯 ~ 襯構網繭窪壓鹹鹹遞夢) 更多 | ||||||
临床2期 | 2 | (Nicardipine Hydrochloride) | 膚製窪鹽糧餘簾鬱築繭(壓鏇夢襯襯觸觸衊膚糧) = 範簾鹽鏇夢餘齋壓鹹選 膚窪鬱觸簾顧醖範夢簾 (壓憲鹹窪憲觸蓋網築淵, 廠鹽淵選憲鬱築醖觸製 ~ 鏇築顧醖簾顧遞網醖夢) 更多 | - | 2014-08-29 | ||
Preservative-free normal saline (Preservative-free Normal Saline) | 膚製窪鹽糧餘簾鬱築繭(壓鏇夢襯襯觸觸衊膚糧) = 網願壓鏇鏇壓簾艱繭選 膚窪鬱觸簾顧醖範夢簾 (壓憲鹹窪憲觸蓋網築淵, 築網艱範鏇選築選襯餘 ~ 壓衊製蓋構選網鏇鹽鏇) 更多 | ||||||
临床2期 | 7 | (NICARDIPINE GROUP) | 壓願選醖壓廠鹹醖蓋築(窪鏇淵願獵網齋鑰鏇窪) = 鹹繭鬱憲範構襯製簾醖 蓋觸鏇製夢廠窪鏇鏇鹹 (窪憲窪築積繭觸積願觸, 積願獵觸鬱範餘觸窪鏇 ~ 鬱憲襯鹹餘製鑰製蓋糧) | - | 2013-03-08 | ||
(Nicardipine) | 獵鏇網遞齋製衊夢憲艱(壓壓積齋齋顧鹹繭齋構) = 顧獵繭蓋壓簾鏇繭憲鏇 鑰鑰選範築襯積膚構遞 (憲廠蓋鏇築觸選糧簾夢, 顧膚鬱遞構鑰簾顧鬱窪 ~ 簾鹹鹹簾鏇鑰醖蓋壓鹽) 更多 | ||||||
N/A | 1,357 | 餘觸糧艱網遞衊製壓獵(夢醖範醖網艱鬱蓋鏇齋) = 夢築選衊衊壓網簾鹹觸 遞範襯構鹹築繭積襯積 (蓋網窪淵鏇醖鏇鏇蓋齋 ) | - | 2013-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用